<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170998</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_DMTD_III</org_study_id>
    <nct_id>NCT04170998</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical
      Trial to Evaluate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and
      Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate
      Glycemic Control
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 14, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c (%) After 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG(mg/dL) After 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c response rate(&lt;7.0% ,&lt;6.5%) After 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 7-point SMBG After 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Evogliptin 5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evogliptin Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin 5mg</intervention_name>
    <description>Participants receive Evogliptin 5mg orally once a day</description>
    <arm_group_label>Evogliptin 5mg group</arm_group_label>
    <other_name>Suganon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin Placebo</intervention_name>
    <description>Participants receive placebo to match Evogliptin 5mg orally once a day</description>
    <arm_group_label>Evogliptin Placebo group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Participants receive Dapagliflozin orally once a day</description>
    <arm_group_label>Evogliptin 5mg group</arm_group_label>
    <arm_group_label>Evogliptin Placebo group</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ≥ 1000mg</intervention_name>
    <description>Metformin are administered at the same dose and formulation.</description>
    <arm_group_label>Evogliptin 5mg group</arm_group_label>
    <arm_group_label>Evogliptin Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type II diabetes mellitus aged 19 years or older

          -  Subjects who performed Dual therapies (complex allowed) for one of the following,
             along with meals and exercise therapy

               1. Subjects who are receiving metformin ≥ 1000 mg/d and dapagliflozin 10 mg/d at the
                  same dose for at least 8 weeks prior to the screening visit

               2. Subjects who are receiving metformin ≥ 1000 mg/d and SGLT-2 inhibitor except for
                  dapagliflozin at the same dose for at least 8 weeks prior to the screening visit

          -  Subjects with 7.0%≤HbA1c≤10.5% at screening visit

          -  Subjects with fasting plasma glucose ≤ 270mg/dL at screening visit

          -  Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening visit

        Exclusion Criteria:

          -  Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic
             ketoacidosis, diabetic coma, pre-coma, lactic acidosis, and acute or chronic metabolic
             acidosis

          -  patients with Hypopituitarism or adrenal insufficiency, pulmonary infarction, severe
             pulmonary dysfunction and other hypoxemia

          -  Patients with severe infectious disease or severe traumatic systemic disorders

          -  End stage renal disease or dialysis patients

          -  Patients with Galactose intolerance, Lapp lactase deficiency, glucose-galactose
             malabsorption

          -  Subjects with Liver cirrhosis, chronic active hepatitis B or C, cholecystitis,
             acromegaly, asthma or major skin allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kun Ho Yoon</last_name>
    <phone>82-2-2258-6007</phone>
    <email>yoonk@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St, Mary's Hospital,The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

